Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular, Cowen Ink $40M Stock Sale Deal

NEW YORK (GenomeWeb) — HTG Molecular Diagnostics said after the close of the market on Wednesday that it has signed a sales agreement with Cowen for the sale from time to time of $40 million of HTG's common stock.

The shares will be sold to or through Cowen though HTG is not obligated to sell any shares under the agreement.

HTG said that net proceeds will be used for working capital and general corporate purposes, including capital expenditures and research and development, sales and marketing, and general and administrative expenses. Net proceeds may also be used to fund acquisitions or investments in businesses, products, and technologies that are complementary to HTG's.

Last week, HTG said that it ended 2018 with $8.4 million in cash and cash equivalents and $22.7 million in short-term investments.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.